Clinical Report: The Challenges of Bringing Retinal Therapies to Market
Overview
At Eyecelerator 2026, industry leaders described how clinical efficacy is only one part of bringing retinal therapies to patients. Trial design and endpoints, regulatory engagement, patient recruitment, manufacturing, financing, reimbursement, and treatment-delivery logistics can also shape development and access.
Background
Retinal therapies span pharmaceuticals, gene and cell therapies, implants, and AI-enabled technologies, each with distinct development and implementation considerations. The panel discussion emphasized that trial design must account for disease heterogeneity, recruitment constraints, and whether conventional visual acuity measures capture meaningful effects, particularly in severe retinal degeneration. Related reporting has also described operational pressures on ophthalmic trial sites and the difficulty of translating encouraging early-stage results into later-stage success. AAO Preferred Practice Pattern guidelines provide a clinical reference for retinal disease management, while regulatory discussions continue to address efficacy endpoints for emerging therapies.
Data Highlights
The source article reports panel observations and development considerations but provides no numerical trial results or quantitative comparisons.
Key Findings
- Panelists said startups may make decisions quickly but devote substantial resources to fundraising, whereas larger organizations have greater financial and technical capabilities but more complex decision processes.
- Erin Kimbrel said developers need to establish a compelling value proposition early, noting that incremental improvement may not be sufficient to secure resources across competing programs.
- Daniela Ferrara described potential uses of AI-based imaging analysis to identify eligible participants, develop more sensitive endpoints, and support trial design; she also noted that regulatory considerations depend on how the technology is used, especially when an AI-derived measure is an efficacy endpoint.
- Panelists called for endpoints that reflect treatment mechanism and patient-relevant function, particularly when visual acuity may not adequately capture effects in severe retinal degeneration.
- For rare retinal diseases, panelists identified recruitment, natural-history data, and partnerships with experienced investigators as development challenges; they also described collaborations with academic institutions and external research partners.
- Manufacturing was identified as a concern for cell and gene therapies. Kimbrel said process improvements and automation had helped reduce costs and variability; related reporting has also described trial-site and recruitment pressures in retinal research.
Clinical Implications
The panelists’ comments support early regulatory engagement and careful selection of endpoints suited to a therapy’s mechanism and intended patient-relevant effects. Developers and trial teams may also need to plan for disease-specific recruitment, external partnerships, imaging-data standardization, and manufacturing requirements; these are considerations reported by the panel, not comparative clinical evidence.
Conclusion
The Eyecelerator discussion characterized retinal therapy development as a coordinated clinical, regulatory, operational, and commercial undertaking. Panelists emphasized that demonstrating efficacy alone does not resolve the challenges of development and delivery.
Related Resources & Content
- Retinal Physician, 2023 -- Overcoming Retina Clinical Trial Challenges With Tailored Solutions
- Retinal Physician, 2017 -- Genentech's Promising Retina Pipeline
- Retinal Physician, 2026 -- Biogen Signals Long-Term Commitment to Retina
- American Academy of Ophthalmology -- Preferred Practice Pattern® Guidelines: Ophthalmology
- Retinal Physician — The Retinal Drug-Delivery Pipeline
- Preferred Practice Pattern® Guidelines: Ophthalmology
- AAO 2026: Closing the gaps in geographic atrophy treatment
- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration - Ophthalmology
- DailyMed - IZERVAY- avacincaptad pegol injection
- theorized to be important mediators of inflammation in AMD.
- Preferences and Trends (PAT) Survey - The American Society of Retina Specialists
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







